Ivonescimab, the new drug, was found in a trial conducted in China to have bested Keytruda, the blockbuster medication ...

Chinese biotech company Akeso developed a lung cancer drug Ivonescimab, which outperformed Merck's Keytruda in trials. This ...

AstraZeneca signed a $1.92 billion deal with China’s CSPC Pharmaceutical Group (CSPC) last year to develop cardiovascular medication, and Merck has a $2 billion agreement with China’s Hansoh ...

Q4 2024 Earnings Call Transcript February 24, 2025 Operator: Good morning and welcome to Summit Therapeutics Fourth Quarter and Year End 2024 Earnings and Update Call. All participants will be in ...

Pfizer has partnered with Summit Therapeutics to evaluate ivonescimab, a PD-1/VEGF bispecific antibody, in combination with ...

Mitsubishi Electric Corporation (TOKYO: 6503) announced today that it has developed the world's first "Operation Log-driven Development Technology" for the development of systems that facilitate and ...

(9926) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT ) has entered into a clinical trial collaboration with Pfizer Inc. (NYSE: PFE ...

ADA, a leader in data and AI-driven digital transformation and all-in-one authentication solutions, and IPification, a pioneer in seamless mobile authentication, have announced their strategic ...

Akeso Inc. has announced that Summit Therapeutics Inc. (SMMT), its partner for ivonescimab, has entered into a clinical trial ...

The American Heart Association says nearly half of all adults in the U.S. have some form of cardiovascular disease. We've all heard a poor diet, lack of exercise and smoking can lead to it, but ...

Summit Therapeutics established a clinical trial collaboration with Pfizer to develop ivonescimab for NSCLC and solid tumors.